Moderna posts quarterly sales beat, smaller loss than expected

(Reuters) -Moderna on Thursday reported quarterly revenue that beat Wall Street estimates but came in dramatically lower than the previous year when demand for COVID-19 vaccines was higher. Sales of Moderna’s COVID-19 shot Spikevax, its only marketed product, dropped 91% from the previous year to $167 million for the quarter but surpassed analysts’ expectations of $97.5 million. The Cambridge, Massachusetts-based company reaffirmed that it expects to receive approval from regulators for its respiratory syncytial virus (RSV) vaccine in time for it to be included in this fall's U.S. vaccine campaign.

Related Keywords

New York , United States , Bengaluru , Karnataka , India , Leroy Leo , Patrick Wingrove , Sonali Paul , , Moderna , Rsv Vaccine , Covid , Cost Of Sales , Vaccines ,